Intl Stem Cell Corp (ISCO) 0.0530 $ISCO
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 395.42 (+4.18), ACOR: 30.71 (+0.67), GSK: 44.66 (-0.11), AZN: 68.74 (-0.55), ATHX: 1.33 (+0.06), CUR: 1.71 (+0.01)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.37 (-0.01), LPTN: 1.75 (-0.08), CNCE: 14.20 (+0.07), ATHX: 1.33 (+0.06), KPTI: 27.02 (+2.21), CUR: 1.71 (+0.01)
International Stem Cell Corporation Announces 2015 First Quarter Results
Marketwired - Wed May 13, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced first quarter financial results for the period ended March 31, 2015.
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Marketwired - Tue Apr 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has published the results of two proof of concept studies that demonstrate the safety and efficacy of the company's readily expandable stem cell derived treatment of Parkinson's disease in both non-human primate and rodent animal models.
International Stem Cell Corporation Presents Data From Parkinson's Disease Program at AAN Annual Meeting
Marketwired - Tue Apr 14, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has been selected to give a platform presentation on its preclinical studies in Parkinson's at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. ISCO's chief scientific officer, Ruslan Semechkin, Ph.D., will discuss the data at the "Parkinson's Disease" scientific session (s48.007), on Thursday, April 23rd at 4:45 pm in a talk entitled "Neural Stem Cell Based Therapy for Parkinson's Disease."
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 3.74 (+0.05), APRI: 1.34 (-0.04)
Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
The Pump Stopper - at Seeking Alpha - Tue Apr 07, 11:23AM CDT
I believe Cellular Biomedicine (NASDAQ: CBMG ) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside. CBMG was previously focusing on Nintendo screens...
NBS: 2.37 (-0.01), IBB: 360.30 (+4.69), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells
Marketwired - Tue Apr 07, 7:30AM CDT
Human parthenogenetic neural stem cells (ISC-hpNSC) can significantly reduce neurological dysfunction after a stroke in animal models, according to recent experiments conducted by International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products.
InsiderInsights.com Daily Round Up 4/2/15: AGCO, BH, RWC, VNCE
InsiderInsights - at Seeking Alpha - Fri Apr 03, 7:27AM CDT
LBTYK: 49.67 (+0.24), OLED: 51.12 (+0.73), GMAN: 6.34 (-0.44), UNF: 115.35 (+1.25), AGCO: 50.99 (-0.15), LNG: 77.11 (+1.25), VNCE: 18.28 (+0.14), LM: 54.52 (-0.17), SNFCA: 6.16 (-0.02), K: 64.64 (-0.59), BH: 356.85 (+3.78), RCAP: 7.87 (+0.04), SCMP: 16.04 (+0.10), RWC: 5.80 (+0.06), COST: 145.06 (+0.23), SIX: 49.47 (-0.42), DAVE: 23.61 (-0.54)
International Stem Cell's (ISCO) CEO Dr. Simon Craw on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 5:16PM CDT
International Stem Cell Corporation Announces 2014 Fourth Quarter and Year-End Results
Marketwired - Tue Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2014.
Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 20.27 (+0.75), ARWR: 6.18 (-0.11), SGMO: 12.31 (+0.80), XON: 41.17 (+1.09), KMDA: 4.20 (-0.20), IBIO: 0.92 (+0.03)
International Stem Cell Corporation Receives Key Stem Cell Patent in Japan
Marketwired - Tue Mar 17, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Japan Patent Office has granted ISCO's patent covering methods of making a bank of human stem cells from parthenogenetically activated eggs, significantly strengthening the company's intellectual property position and partnering ability in Japan.
International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
Marketwired - Tue Feb 03, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today announced that the Company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 395.42 (+4.18), ACOR: 30.71 (+0.67), GSK: 44.66 (-0.11), AZN: 68.74 (-0.55), ATHX: 1.33 (+0.06), CUR: 1.71 (+0.01)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.37 (-0.01), LPTN: 1.75 (-0.08), CNCE: 14.20 (+0.07), ATHX: 1.33 (+0.06), KPTI: 27.02 (+2.21), CUR: 1.71 (+0.01)
International Stem Cell Corporation Announces 2015 First Quarter Results
Marketwired - Wed May 13, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced first quarter financial results for the period ended March 31, 2015. International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Marketwired - Tue Apr 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has published the results of two proof of concept studies that demonstrate the safety and efficacy of the company's readily expandable stem cell derived treatment of Parkinson's disease in both non-human primate and rodent animal models.
International Stem Cell Corporation Presents Data From Parkinson's Disease Program at AAN Annual Meeting
Marketwired - Tue Apr 14, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has been selected to give a platform presentation on its preclinical studies in Parkinson's at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. ISCO's chief scientific officer, Ruslan Semechkin, Ph.D., will discuss the data at the "Parkinson's Disease" scientific session (s48.007), on Thursday, April 23rd at 4:45 pm in a talk entitled "Neural Stem Cell Based Therapy for Parkinson's Disease."
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 3.74 (+0.05), APRI: 1.34 (-0.04)
Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
The Pump Stopper - at Seeking Alpha - Tue Apr 07, 11:23AM CDT
I believe Cellular Biomedicine (NASDAQ: CBMG ) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside. CBMG was previously focusing on Nintendo screens...
NBS: 2.37 (-0.01), IBB: 360.30 (+4.69), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells
Marketwired - Tue Apr 07, 7:30AM CDT
Human parthenogenetic neural stem cells (ISC-hpNSC) can significantly reduce neurological dysfunction after a stroke in animal models, according to recent experiments conducted by International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products.
InsiderInsights.com Daily Round Up 4/2/15: AGCO, BH, RWC, VNCE
InsiderInsights - at Seeking Alpha - Fri Apr 03, 7:27AM CDT
LBTYK: 49.67 (+0.24), OLED: 51.12 (+0.73), GMAN: 6.34 (-0.44), UNF: 115.35 (+1.25), AGCO: 50.99 (-0.15), LNG: 77.11 (+1.25), VNCE: 18.28 (+0.14), LM: 54.52 (-0.17), SNFCA: 6.16 (-0.02), K: 64.64 (-0.59), BH: 356.85 (+3.78), RCAP: 7.87 (+0.04), SCMP: 16.04 (+0.10), RWC: 5.80 (+0.06), COST: 145.06 (+0.23), SIX: 49.47 (-0.42), DAVE: 23.61 (-0.54)
International Stem Cell's (ISCO) CEO Dr. Simon Craw on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 5:16PM CDT
International Stem Cell Corporation Announces 2014 Fourth Quarter and Year-End Results
Marketwired - Tue Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2014. Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 20.27 (+0.75), ARWR: 6.18 (-0.11), SGMO: 12.31 (+0.80), XON: 41.17 (+1.09), KMDA: 4.20 (-0.20), IBIO: 0.92 (+0.03)
International Stem Cell Corporation Receives Key Stem Cell Patent in Japan
Marketwired - Tue Mar 17, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Japan Patent Office has granted ISCO's patent covering methods of making a bank of human stem cells from parthenogenetically activated eggs, significantly strengthening the company's intellectual property position and partnering ability in Japan.
International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
Marketwired - Tue Feb 03, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today announced that the Company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements.
